799267-93-9

Upstream product

• 133697-14-0 2,6-anhydro-7,8,9-trideoxy-D-glycero-L-galacto-non-8-enitol 
• 53263-18-6 allyl 2,3,4,6-tetra-O-acetyl-α-D-galactopyranoside 
• 100-39-0 benzyl bromide 
• 25878-60-8 D-galactose pentaacetate 
• 82659-55-0 3-(2',3',4',6'-tetra-O-benzyl-α-D-galactopyranosyl)prop-1-ene 

Downstream Products

• 799267-94-0 2,3,4,6-tetra-O-benzyl-1-deoxy-α-D-galactopyranosylethene 
• 799268-03-4 [(E)-(S)-1-((4S,5R)-2,2-Dimethyl-5-tetradecyl-[1,3]dioxolan-4-yl)-3-((2R,3S,4R,5S,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yl)-allyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Subtle stereochemical and electronic effects in iridium-catalyzed isomerization of C-allyl glycosides

Stereoselective isomerization of C-allyl glycosides into (E)-C-vinyl glycosides or (2)-exo-glycals was carried out in the presence of the cationic iridium(I) catalyst [(Ph2MeP)2Ir(cod)PF6]. The products of the isomerization were affected by the relative 1,2-stereochemical relationships and by the nature of the protecting groups. These effects are discussed along with a plausible reaction mechanism.

Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases

The invention is directed to novel compounds of formulae (I), (II) and (III): wherein X is O or NH; R3 is OH or a monosaccharide and R4 is hydrogen, or R3 is hydrogen and R4 is OH or a monosaccharide; R5 is hydrogen or a monosaccharide; and pharmaceutically acceptable salts or esters thereof. The invention is also directed to the use of the compounds both directly and as immune adjuvants for treating cancer, infectious diseases and autoimmune diseases. The invention is also directed to syntheses of the intermediates which can be used to make these novel compounds.